In Vivo Validation of Thymidylate Kinase (TMK) with a Rationally Designed, Selective Antibacterial Compound
Citations Over TimeTop 10% of 2012 papers
Abstract
There is an urgent need for new antibacterials that pinpoint novel targets and thereby avoid existing resistance mechanisms. We have created novel synthetic antibacterials through structure-based drug design that specifically target bacterial thymidylate kinase (TMK), a nucleotide kinase essential in the DNA synthesis pathway. A high-resolution structure shows compound TK-666 binding partly in the thymidine monophosphate substrate site, but also forming new induced-fit interactions that give picomolar affinity. TK-666 has potent, broad-spectrum Gram-positive microbiological activity (including activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus), bactericidal action with rapid killing kinetics, excellent target selectivity over the human ortholog, and low resistance rates. We demonstrate in vivo efficacy against S. aureus in a murine infected-thigh model. This work presents the first validation of TMK as a compelling antibacterial target and provides a rationale for pursuing novel clinical candidates for treating Gram-positive infections through TMK.
Related Papers
- → Thymidylate synthase and drug resistance(1995)153 cited
- → Tumor Cell Responses to Inhibition of Thymidylate Synthase(1988)6 cited
- → Enhancement of thymidylate synthase inhibition(1993)5 cited
- Current status of thymidylate synthase inhibitors in cancer therapy(2005)
- → The therapeutic efficacy of thymidylate synthase on pemetrexed treatment of lung adenocarcinoma(2017)